Table 1 Demographic and clinical characteristics at presentation of the enrolled patients.

From: Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19

Patient's characteristics

SARS-CoV-2

SOF/VEL Treated

SARS-CoV-2

untreated Patients

p = 

Number

30

90

 

Male (%)

66

62

ns

Coinfected SARS-CoV-2/HCV, n

18

0

 

Median Age, yrs (range)

54 (23–77)

53 (38–86)

ns

Fever and/or cough and/or anosmia, %

67

70

ns

Radiology

Ground glassy opacity, %

70

77

ns

Pneumonia, %

6,6

8.8

ns

PaO2/FIO2 ratio, median range]

330 [280–438]

338 [282–448]

ns

Required O2 therapy, %

20

22

ns

  1. ns = not significant.